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Abstract
Background Liver metastases (LMs) from thyroid cancer (TC) are relatively uncommon in clinical practice and their man-
agement is challenging. Interventional radiology loco-regional treatments (LRTs), including radiofrequency ablation (RFA) 
and trans-arterial chemoembolization (TACE), have been successfully employed to treat LMs from various types of cancer.
Methods We analyzed the role of LRTs in the management of unresectable LMs from differentiated and medullary TCs 
performed at our institution from 2015 to 2020. A review of the available English literature regarding this topic was also 
performed.
Results Six hepatic LRTs were performed in 4 TC patients with LMs, in 2 cases after the start of treatment with a tyrosine 
kinase inhibitor (TKI). A partial response was obtained in 2 patients; the diameter of the largest targeted lesion was 18 mm 
in both of them. The remaining procedures were performed on larger lesions and a stable disease was achieved in all but 
one case. Acute LRT-related complications were transient and mild. In literature, the largest studies were focused on TACE 
in LMs from MTC, showing good tolerance and remarkable disease control, especially in case of limited liver tumour 
involvement.
Conclusion LRTs for LMs represent a valuable option for the treatment of metastatic TC in case of isolated hepatic progres-
sion or for symptoms relief, also after the start of TKI treatment as part of a multimodal approach. The best disease control 
is obtained when hepatic metastatic burden is limited. These procedures are generally well tolerated; however, a cautious 
multidisciplinary selection of the candidates is mandatory.
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Introduction
Thyroid cancer (TC) is the most frequent endocrine malig-
nancy. Differentiated thyroid carcinoma (DTC) arises from 
the epithelial follicular cells and represents the 80–90% of 
TCs [1]. Medullary thyroid cancer (MTC), instead, has a 
neuroendocrine origin and is less common (5–10% of all 
TCs), but it is usually more aggressive [2]. Localized TC has 
generally a good prognosis, while the development of dis-
tant metastases significantly increases morbidity and mortal-
ity; in case of disseminated disease, therapeutic strategies 
are limited [1].
Liver metastases (LMs) are quite common in advanced 
MTC, being found in nearly half of the patients with sec-
ondarisms [3]; on the contrary, lung and bone are the most 
frequent DTC metastatic sites, while LMs are quite rare [4]. 
Given the relative rarity of metastatic forms of TC, LMs 
from both DTC and MTC are, overall, relatively uncommon 
in clinical practice. Moreover, being frequently associated 
with metastatic spread in other distant organs, they are not 
amenable to surgery with a curative intent in most cases [5].
In the last decades, non-surgical loco-regional treatments 
(LRTs) including thermo-ablation techniques, such as radi-
ofrequency ablation (RFA) or microwave ablation (MWA), 
and embolization techniques, such as trans-arterial emboli-
zation/chemoembolization (TAE/TACE), have been increas-
ingly employed to treat both primary hepatic malignancy [6] 
and LMs from various types of cancer [7–9]. According to 
the ATA guidelines [10], image-guided LRTs can be per-
formed to provide palliation or radical local tumour con-
trol in the oligo-metastatic setting; according to the specific 
needs of the patient, different treatment can be combined. 
Specifically, LRTs have been performed in both MTC and 
DTC patients [11–13]. The aim of this study was to describe 
the LRTs for LMs from TC performed at our institution and, 




Patients who underwent trans-arterial and/or percutaneous 
ablation for LMs from DTC or MTC from January 2015 
to December 2020 (either as single or multiple treatments) 
were included.
LRTs were performed by expert interventional radiolo-
gists after multidisciplinary tumour board discussion, which 
involved endocrinologists, oncologists, radiation therapists, 
interventional radiologists, surgeons, pathologists, and 
nuclear medicine specialists.
Patients were considered eligible in case of first radiologi-
cal detection of unresectable LM, or after the evidence of 
hepatic progression in absence of other metastases or with 
stable extrahepatic disease. If patients had been previously 
started a systemic therapy, LRTs were performed in case 
of progressive LMs when extrahepatic disease was stable. 
In these cases, the goal of LRTs was the achievement of a 
good control of liver disease allowing the prosecution of the 
systemic treatment.
A careful pre-evaluation of the history and the previous 
images of the candidates for LRTs was always performed in 
order to minimize the risk of complications and identify the 
most suitable procedure. Both severe liver insufficiency and 
uncorrected coagulopathy represented absolute contraindica-
tions for LRTs. LMs located at the hepatic hilum were not 
considered suitable for RFA/MWA, since a possible damage 
of main biliary ducts and vessels might occur.
Regarding the number and the size of LMs, the evaluation 
was performed on a case-by-case basis.
TACE was preferred in case of multiple LMs with bilobar 
liver involvement and adequate arterial vascularization of 
the lesions, while RFA/MWA was employed when a single/
few lesions had to be treated. In case of persistence of vital 
tissue or hepatic progression of disease, a second LRT was 
considered. If feasible, two different procedures could be 
combined (e.g. RFA/MWA in conjunction with TACE in 
case of a large and highly vascularised LM).
All patients signed a written informed consent prior to 
LRT.
TACE was performed in the angio-suite under fluoro-
scopic guidance; femoral artery was cannulated, and selec-
tive catheterization of the hepatic artery with subsequent 
superselective catheterization of the feeding vessels of the 
tumour was performed. Drug-eluting beads (70–150-μm 
diameter particles) loaded with 50 mg of epirubicin were 
delivered intra-arterially.
Ablation was performed under ultrasound guidance: radi-
ofrequency needle or MWA antennas were introduced into 
the LM to induce thermal tumour cell necrosis; the ablation 
area was evaluated with contrast-enhanced ultrasound at the 
end of the procedure.
In case of treatment with tyrosine kinase inhibitors (TKIs) 
with anti-VEGF (vascular endothelial growth factor) effect, 
the systemic treatment was temporarily interrupted in order 
to avoid potential bleeding.
After LRTs, contrast-enhanced computed tomography 
(CT) control was normally performed nearly 1 month later. 
Hepatic radiological response to LRT was assessed accord-
ing to Response Evaluation Criteria in Solid Tumours 
(RECIST) criteria 1.1 [14]. Duration of the hepatic tumour 
response after the procedure was also assessed. LRT-related 
adverse events (AEs) in the first month after the procedure 
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were recorded according to Common Terminology Criteria 
Adverse Events (CTCAE), version 5 [15].
Baseline characteristics of the patients included in the 
analysis are summarized descriptively using median and 
range or number and percentages.
Results
From January 2015 to December 2020, 17 patients with TC 
and LMs (8 DTC and 9 MTC) were followed at our institu-
tion. The majority of them (12 out of 17) showed progres-
sion of both LMs and extrahepatic disease; therefore, sys-
temic therapy was preferred and no LRTs focused on LMs 
was performed at our centre. In one case (DTC), there was 
a single large LM in the absence of extrahepatic disease and 
the patient was referred for surgical resection.
Six hepatic LRTs were performed in the remaining 4 
TC patients with LMs. As displayed in Table 1, LRTs were 
TACE (n = 3), RFA (n = 1), MWA (n = 1), or MWA com-
bined with TACE (n = 1). Median age at diagnosis of TC 
was 37 years (range 20–65 years); all patients were female 
(2 MTC and 2 DTC). Median time from initial diagnosis to 
the detection of LM was 5.5 years (range 3.2–18.3 years); 
liver was the first metastatic site in 2 patients (both MTC). 
At the time of LRT, 2 patients (both DTC) had concurrent 
stable extrahepatic disease (lung and bone metastases in both 
patients and brain secondarisms in one case). Median time 
from the diagnosis of LM to the first LRT was 6 months 
(range 5–12 months); 2 patients were submitted to a second 
hepatic LRT after 8 and 11 months from the previous pro-
cedure, respectively.
A partial response was obtained in 2 cases, which 
lasted 18 months in one patient and is still confirmed after 
20 months of follow-up in the other case. In both of them, 
the maximum diameter of the largest targeted lesion was 
18 mm.
The remaining procedures (4/6) were performed on larger 
lesions (range of maximum diameter 32–55 mm): in one 
patient (MTC with somatic M918T RET mutation), progres-
sive disease (PD) was observed 40 days after the first LRT, 
with subsequent need for TKI therapy; in other cases, stable 
disease (SD) was achieved and maintained for more than 
6 months (Fig. 1).
Acute LRT-related complications were transient and mild 
(G1–G2): abdominal pain in 3 patients, liver function test 
abnormalities in 2 cases, nausea, and toracic pain in one 
case each.
Table 1  Main data about MTC and DTC patients treated with LRTs for LMs
DTC differentiated thyroid cancer, LRT loco-regional treatment, LM liver metastasis, MTC medullary thyroid cancer, MWA microwave abla-
tion, PD disease progression, PR partial response, RFA radiofrequency ablation, SD stable disease, TACE trans-arterial chemoembolization, TKI 
tyrosine kinase inhibitor
















Multiple - No TACE 3 18 mm PR
2 MTC
(23 years)
Multiple - No TACE 2 42 mm PD
Yes (vandetanib) RFA 2 18 mm PR
3 DTC
(55 years)
Single Bone, lung No MWA 1 55 mm SD
No MWA + TACE 1 50 mm SD
4 DTC
(71 years)
Multiple Bone, brain, lung Yes
(lenvatinib)
TACE 4 32 mm SD
Fig. 1  Morphological variation 
of subglissonian LM localized 
in segment IVb (patient no. 3) 
before the second LRT (a), after 
1 month (b), and after 7 months 
(c) from the second LRT
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Table 2  Summary of the available English articles concerning LRTs for LMs from TC



















RFA MTC 1 NA* NA* NA* NA*
Guglielmi et al. 
[18]










RFA1 MTC 6 NA* NA* NA* NA*
Elvin et al.
 [21]
RFA MTC 2 NA* NA* NA* NA*
Lorenz et al.
 [22]
TACE MTC 11 Multiple
(size not 
known)
Yes (88%) PR 3 (n = 5)
SD 3 (n = 4)
PD 3 (n = 1)







(n = 1; G3)
hypertensive crisis with 
myocardial  infarction4
(n = 1; G5)
Fromigué et al.
 [11]
TACE MTC 12 Multiple
(median 38 mm; 
range 25–98)
Yes (40%) PR (n = 5)
SD (n = 5)







necrosis with pain and 
fever
(n = 1; G3)
Mazzaglia et al.
 [23]
RFA1 MTC 9 NA* NA* NA* NA*
Wertenbroek et al. 
[12]
RFA + TAE FTC 1 Multiple
(38 mm)
- NA Fever
RFA1,2 MTC 2 Multiple
(70 mm)
Yes (100%) Yes 3 (n = 2) Burn wounds (n = 1)
Akyildiz et al.
 [24]
RFA1 MTC 11 NA* NA* NA* NA*
Yasui et al.
 [25]











TAE MTC 1 Multiple
(size not 
known)














(n = 1; G3)
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Two LRTs were performed in patients who were being 
treated with TKIs (vandetanib or lenvatinib). Systemic ther-
apy was interrupted before and after the procedure, for a 
total of 11 days in one patient and 15 days in the other case; 
no hemorrhagic complications were recorded.
Literature Review
Available data regarding LRTs of LMs from TC are 
scarce and based on small retrospective cohort studies or sin-
gle case reports. A PubMed search was performed to iden-
tify all relevant English literature. Keywords (“loco-regional 
treatment OR therapy,” “TACE,” “RFA”) and medical sub-
ject heading terms (“thyroid cancer OR carcinoma,” “liver 
OR hepatic metastases”) were used to identify all potentially 
relevant articles. A subsequent manual crossreferencing was 
performed to find further pertinent studies. Table 2 summa-
rizes current published reports about this topic [8, 11–13, 
16–28].
According to the retrieved articles, a total of 75 patients 
with TC have been treated with LRTs for LMs. MTC was 
the most represented histology (68/75); the majority of 
DTC patients had papillary thyroid cancer (4/7), while the 
remaining were affected by follicular (n = 2) or Hurthle cell 
(n = 1) carcinoma. The most commonly employed LRTs 
were TACE and RFA (both laparoscopic and percutane-
ous), while patients were less frequently treated with TAE, 
MWA, percutaneous ethanol injection (PEI), interstitial laser 
photocoagulation (ILP), and transcatheter arterial radioem-
bolization (TARE).
In some of the published reports, TC patients with LMs 
have been included in larger cohorts of patients treated 
with LRTs for LM from other solid tumours (especially 
neuroendocrine tumours) or for primary hepatic malignan-
cies [8, 17, 20, 21, 23, 24]. In these heterogeneous cohorts, 
data regarding the subgroups of patients with TC were not 
analysed separately; hence, no definitive conclusion con-
cerning their outcomes can be retrieved. Only a small num-
ber of articles specifically focusing on TC patients have been 
published, and the majority of them are case reports [11–13, 
16, 18, 19, 22, 25–28].
The largest studies included in this review were focused 
on TACE in LMs from MTC, showing that this technique is 
a feasible and effective procedure [11, 13, 22]. The imaging 
assessment of LMs after LRTs showed that PR rate var-
ied from nearly 50% [11, 22] to 100% of the patients [13]; 
SD was the most common response in another significant 
proportion of patients (range 36–42%), while PD was less 
frequent. Some authors stated that radiological response 
seemed to be associated to the initial extent of liver involve-
ment, with better responses in patients with less than 30% 
of the liver involved [11]. However, others demonstrated 
a beneficial effect of TACE even in case of a greater liver 
involvement up to 50% and with larger metastatic lesions 
(> 30 mm) [13]. The response was also durable, since all 
of these studies showed more than 12 months of ongoing 
response (range 14–38 months) [11, 13, 22]. TACE appears 
to be valuable also in controlling disease-related symptoms, 
since it improved both intractable diarrhoea and abdominal 
pain [11, 13, 22].
TACE was usually well tolerated in the majority of 
patients: nausea, vomiting, abdominal pain, fever (post-
embolization syndrome), and elevation of liver enzymes 
were usually mild and transient. Few patients developed 
more severe AEs: hypertensive crisis in two patients [13, 
22], dissection of hepatic artery, tumour necrosis syndrome, 
AEs adverse events, FTC follicular thyroid carcinoma, HTC Hurthle cell carcinoma, ILP interstitial laser photocoagulation, MTC medullary thy-
roid carcinoma, MTS metastases, MWA microwave ablation, NA not available, PEI percutaneous ethanol injection, PD progressive disease, PR 
partial response, RFA radiofrequency ablation, RT radiotherapy, SD stable disease, TACE transcatheter arterial chemoembolization, TAE tran-
scatheter arterial embolization, TARE transcatheter arterial radioembolization
1 Laparoscopic approach
2 Laparotomic approach
3 No RECIST-based criteria
4 In a patient with concomitant unrecognized LMs from pheocromocytoma
*These data are not available since they refer to cohorts of patients with LMs from various tumours in which no subgroup analysis was per-
formed
Table 2  (continued)



















NA* NA* NA* NA*
Kesim et al. 
 [28]
TARE PTC 1 Single
(45 mm)
- PR NA
827Journal of Gastrointestinal Cancer (2021) 52:823–832
1 3
and cholecystitis in one patient each [11, 22, 27]. It is note-
worthy that a greater number of AEs were recorded in 
patients who had been submitted repeatedly to a higher 
number of procedures [22]. A procedure-related death was 
reported in a MEN2A patient with concomitant unrecog-
nized pheochromocytoma LMs [29].
TAE has been reported only twice in MTC, albeit with 
good results (PR in both patients) [19, 27].
RFA has also been employed in the treatment of LMs 
from MTC, but few data are available for specifically evalu-
ating its effectiveness. Wertenbroek and colleagues reported 
good responses with RFA of two large lesions (70 mm), with 
no sign of progression after 5 years of follow-up [12].
Patients with DTC, as expected due to the rarity of this 
metastatic site, represent a minority of those treated with 
LRTs for LM: the only available detailed data are derived 
from few case reports [12, 18, 25, 26, 28].
Both embolization and ablative techniques have been 
employed for the treatment of LMs that were frequently 
single and large (up to 170 mm). Nonetheless, the proce-
dures were effective in controlling the disease: two PR were 
achieved in 45-mm and 170-mm lesions with TARE and 
ILP, respectively [18, 28], and a complete response was 
reported in a 21-mm LM from Hürthle cell carcinoma after 
MWA [26]. The reported AEs were mild and self-limiting.
Discussion
Given their rarity and the frequent association with extra-
hepatic advanced disease, the management of LMs from 
TC is challenging. In recent years, LRTs have emerged as a 
valuable choice in this setting, primarily for treating LMs not 
amenable to surgery, for symptom palliation or as ancillary 
procedures for other systemic therapies in case of LM pro-
gression [30]. Indeed, interventional radiology approaches 
for LMs from TC are also contemplated by the main inter-
national guidelines (see Table 3) [10, 30–32].
There are no stringent criteria on the indications to LRTs 
in TC patients with LMs not only for the lack of reports in 
literature but also since the clinical expertise required for 
these techniques is not widely available. Ablation techniques 
should be considered in case of single or few LMs, if surgery 
is not indicated due to extrahepatic metastatic burden, clini-
cal condition, or patient’s choice; conversely, a trans-arterial 
embolization approach should be preferred in case of diffuse 
liver metastatic deposits, as commonly seen in MTC [13, 
24]. In addition, TACE might be employed also when an 
ablation procedure is contraindicated due to the LM position 
(e.g. near liver hilum or large bile ducts) [21].
Most of the DTC or MTC patients with liver involve-
ment also have metastases to lymph nodes, bones, and 
other organs, and therefore, they require systemic therapies 
(e.g. TKIs, bisphosphonates). In this setting, TACE should 
always be carefully considered; according to our experience 
and the literature [11, 13, 22], it is usually well tolerated, 
inducing both clinical improvement and tumour response 
for prolonged periods of time in the majority of cases. Dete-
rioration in liver function is the major factor determining 
prognosis. The best candidates for TACE should be the 
patients in whom the disease progression occurs mainly 
in the liver, irrespective of the presence of extrahepatic 
metastases.
Table 3  Main recommendations from TC guidelines pertaining the LRTs for LMs from TC
DTC differentiated thyroid cancer, LMs liver metastases, LRTs loco-regional treatments, MTC medullary thyroid cancer, RFA radiofrequency 




DTC Thermal ablation (RFA and cryoablation) may be considered as valid alternatives to surgery
Thermal ablation should be considered prior to initiation of systemic treatment when the individual distant metas-






LRTs should be considered either alongside systemic therapies or alone in case of progression of a single lesion or 
multiple lesions in a single organ, with the aim of controlling symptoms, optimize disease control or delay the 
initiation of systemic treatments and their toxicities. When employed during systemic therapy, TKIs could be 
continued or interrupted temporarily for few days
TACE can be applied to LMs from advanced TC, particularly when LMs are smaller than 30 mm and liver involve-
ment is < 30%, although benefits in prolonging survival or delaying progression are yet unproven




MTC Treatment is indicated in patients with LMs that are large, increasing in size, or associated with symptoms such as 
diarrhoea or pain




DTC, MTC If true solitary lesions are detected, they may be candidates for local ablation
In MTC patients with a dominant lesion that is growing more rapidly than the background disease, local ablation 
(e.g. RFA) may be useful for controlling symptoms, such as diarrhea
If both surgery and RFA are contraindicated, TACE might be an option
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Regarding embolization techniques, the good results 
of TAE, although in a small number of patients, leads to 
speculate that embolization without a chemotherapeutic 
agent could be a good choice for disease control, consider-
ing the added cost and potential AEs associated with TACE 
[12, 19, 27]. A debate focusing on the potential benefit of 
TACE versus TAE in patients with LMs is still ongoing 
[33]. Regarding TACE, no specific chemotherapeutic agent 
can be bound to an embolic particle for metastatic TC. The 
addition of doxorubicin has been shown to be associated 
with an increase in arterial and parenchymal necrosis and 
the establishment of an inflammatory response resulting in 
disturbances in liver metabolism [34]. Rationale for drug-
eluting beads use is avoiding a peak plasma concentration 
of the chemotherapeutic drugs, resulting in exposure of 
the tumour to the therapeutic agents with less exposure of 
healthy liver tissue [35].
In selected cases, ablation and embolization techniques 
could be combined to treat the same lesions: in case of 
insufficient ablation with a single course of RFA, if the LM 
remains hypervascular, a selective cycle of TACE/TAE 
could be applied in order to enhance the response to a sec-
ond RFA procedure [12].
Different lesion size and liver burden have been shown to 
influence the LRTs effectiveness. Data derived from stud-
ies carried out in patients with LMs from different types of 
cancers showed that LRTs seem more successful in smaller 
lesions and in case of limited liver tumour involvement [23, 
24, 36], while a greater number of procedures might be nec-
essary for treating larger LMs [12, 18, 19].
This finding is confirmed by our case series, since 
patients with lesions < 20 mm showed PR, while larger LMs 
remained mostly stable after LRTs. Interestingly, one of our 
patients (n = 3) with a large single LM had to undergo a 
second procedure after a first incomplete ablation, obtaining 
good results with the combined techniques.
Regarding LMs from MTC treated with TACE, a limited 
liver tumour involvement, but not the size of the largest LM, 
was associated with a better structural response [11].
Whether an early loco-regional approach might help to 
control the hepatic disease and delay the need of a systemic 
therapy is still debated; our limited data are insufficient to 
draw definite conclusions about this topic.
Despite the scarcity of available specific data, some les-
sons can be learned from the interventional radiology expe-
rience on other more common oligometastatic disease. For 
instance, a large series about RFA and MWA of 218 colo-
rectal cancer LMs in 136 patients reported a 3-year local 
tumour progression-free survival (LTPFS) of 62%. On mul-
tivariate analysis, independent predictors of worse LTPFS 
were, among the others, minimal ablation margins ≤ 10 mm 
and LM size ≥ 2 cm [37]. Similar to those from colorec-
tal cancer, LMs from TC could be reasonably treated with 
curative percutaneous ablation applying the same criteria 
about tumour size and ablation margins.
More in general, among factors predicting ablation site 
recurrence following percutaneous ablation, the most sig-
nificant is the proximity of the lesion to the blood vessel 
[38]. Whilst a heat sink effect has been reported for RFA in 
the setting of LMs [39], it is unclear whether MWA is simi-
larly affected. Technical differences between RFA and MWA 
including the fact that MWA reaches higher temperatures 
over shorter time periods suggest that MWA may be more 
resilient to heat sinking [40].
Although RECIST criteria are the most widely used 
worldwide [14], they have been found to underestimate 
the response of liver tumours (both primary malignancies 
and LMs) after LRTs [41]. This finding is related to the 
fact that RECIST criteria, evaluating only the shrinkage of 
the lesions, do not take in consideration necrosis and the 
decreased enhancement that characterize the response of 
LMs to both LRTs and new targeted therapies (e.g. TKIs). 
To overcome this limitation, new systems have been pro-
posed [42, 43] that introduced the notion of “viable tumour,” 
the portion of the lesion that show persistent enhancement 
after intravenous contrast administration. New insights in 
the field involving also functional, volumetric, and radiomic 
approaches have been proposed and should be validated in 
future researches [41].
As observed in our series, LRTs are usually well-tolerated 
procedures, with temporary, mild, and manageable AEs. Side 
effects are generally more frequent in patients submitted to 
several LRTs [22]. In patients with LMs from neuroendocrine 
tumours, ablation is a treatment with a low complication rate, 
varying between 2.5 and 5.7% of all reported cases [44], and 
low mortality rate (0.5–1.5%) [45]. TACE overall morbidity 
and grade three-fourths complications are respectively 22.6% 
and 9.2% [46]. The most frequent major complications are 
decompensation with ascites, acute cholecystitis, acute pan-
creatitis, liver abscesses, and renal failure. Post-embolization 
syndrome appears in 20% of patients. Concomitant cardio-
vascular disease is a risk factor for development of complica-
tions [47].
LRTs could be employed also in the context of a multi-
modal strategy. In particular, ablation techniques have been 
shown to increase the effectiveness of radioiodine treatment 
[12, 18]; furthermore, endovascular procedures have been 
successfully employed for tumour debulking before hepatic 
metastasectomy [28]. Among our patients, two were treated 
with LRTs while on systemic therapy with TKIs, with good 
response and tolerance. The outcome of these cases confirms 
that LRTs are valuable options in combination with other 
treatments in advanced TC patients, especially to manage oli-
goprogressive metastatic disease or for symptoms relief [30].
It could be argued that the benefit from anti-angiogenic 
agents might be reduced by the alteration of the intratumoral 
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vascularization by previous LRTs. On the contrary, it is also 
possible that the reduction of metastatic burden facilitates 
the cytostatic action of TKIs. No definite data are available 
in literature regarding this issue.
Conclusion
LRTs for LMs represent a valuable option for the treatment 
of metastatic TC. The best candidates for LRTs are patients 
with unresectable progressive LMs with limited and stable 
extrahepatic disease. In case of isolated hepatic progression, 
LRTs can be performed also after the start of TKI treatment 
as part of a multimodal approach, to reduce the tumour bur-
den and allow the prosecution of the systemic treatment. 
The best disease control is obtained especially when hepatic 
metastatic burden is limited.
These procedures are generally safe and well tolerated; 
however, a multidisciplinary cautious selection of the can-
didates for these procedures is mandatory. Prospective mul-
ticenter randomized studies, including larger number of 
patients with LMs, would be necessary for a better definition 
of the best candidates for LRTs, for treatment timing, and for 
evaluating its efficacy in terms of time to tumour progression 
and long-term survival.
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